Usual Adult Dose for Lymphoma:
560 mg orally once a day until disease progression or unacceptable toxicity
Uses:
-For the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
-For the treatment of adult patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy
Usual Adult Dose for Chronic Lymphocytic Leukemia:
As a single agent or in combination with bendamustine and rituximab or with obinutuzumab:
420 mg orally once daily until disease progression or unacceptable toxicity
Comments:
-Consider administering this drug prior to rituximab or obinutuzumab when given on the same day.
Uses:
-For the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
-For the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion
Usual Adult Dose for non-Hodgkin's Lymphoma:
420 mg orally once a day
Duration of Therapy:
-WM: Until disease progression or unacceptable toxicity
-cGVHD: Until disease progression, recurrence of an underlying malignancy, or unacceptable toxicity
Comments:
-WM: Management of hyperviscosity may include plasmapheresis before and during therapy, which will not require dosing modifications.
-cGVHD: When a patient no longer requires therapy, discontinue this drug considering the medical assessment of the individual patient.
Uses:
-For the treatment of adult patients with Waldenstrom's macroglobulinemia (WM)
-For the treatment of adult patients with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy
Usual Adult Dose for Graft Versus Host Disease:
420 mg orally once a day
Duration of Therapy:
-WM: Until disease progression or unacceptable toxicity
-cGVHD: Until disease progression, recurrence of an underlying malignancy, or unacceptable toxicity
Comments:
-WM: Management of hyperviscosity may include plasmapheresis before and during therapy, which will not require dosing modifications.
-cGVHD: When a patient no longer requires therapy, discontinue this drug considering the medical assessment of the individual patient.
Uses:
-For the treatment of adult patients with Waldenstrom's macroglobulinemia (WM)
-For the treatment of adult patients with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy
 Detailed Imbruvica dosage information
What happens if I miss a dose?
Take the missed dose on the same day you remember it. Take your next dose at the regular time and stay on your once-daily schedule. Do not take 2 doses on the same day.
What happens if I overdose?
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
